A Phase 1 interventional study of TTYP01 single ascending doses and Placebo in Healthy Adult Subjects, sponsored by Shanghai Auzone Biological Technology Co., Ltd.. Completed at 1 site in Australia. Open to participants aged 18 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-01-06.
Sponsored by Shanghai Auzone Biological Technology Co., Ltd. · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is integrated Phase 1, Single centre, Randomized study will be conducted in 3 parts, each with a specific primary objective:
Part A: To characterise the safety and tolerability of TTYP01 in healthy adult subjects; Part B: To evaluate the bioavailability of TTYP01 tablets in healthy adult subjects; Part C: To characterise the food effect of TTYP01 tablets in healthy adult subjects under the fasted or fed condition.
The secondary objectives of the study are to evaluate the pharmacokinetic (PK) profiles of TTYP01 tablets in healthy adult subjects, and the effects of gender on the PK of TTYP01 tablets in healthy adults. In Part A of the study, a total of 32 healthy adult subjects will be enrolled over four consecutive cohorts (8 per cohort), with participants receiving a single dose of TTYP01 at one of four levels (60, 120, 10 or 240 mg), to assess the PK and safety of TTYP01. In Part B, 16 healthy adults will be randomized into 2 groups, and the comparison of the PK of edaravone (TTYP01 and intravenous (IV) edaravone) will be evaluated using a randomized, open-label, four-period crossover design under fasted conditions. In the first crossover period, subjects will receive a single fixed dose of TTYP01 followed by the alternate IV dose after completion of the washout phase, and in the second crossover period, subjects will receive a higher fixed dose of TTYP01 followed by the alternate IV dose after completion of the washout phase. In Part C, 18 healthy subjects will be enrolled to evaluate the effect of food on the PK of TTYP01 using a randomized, open-label, two-period cross-over design. Participants will be randomized into two groups and administered a fixed dose of TTYP01 on Day 1 (Period 1) under the fed conditions and the second dosing day (Period 2) under the fasted conditions, while the other group being administered a fixed dose of TTYP01 on Day 1 (Period 1) under the fasted conditions and the second dosing day (Period 2) under the fed conditions.
Shanghai Auzone Biological Technology Co., Ltd. is the lead sponsor of 5 studies on the registry; 2 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Adequate organ function as evidenced by the following peripheral blood counts or serum chemistry values within 28 days before randomization:
Hepatic function variables:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
In Part A: a single-ascending-dose (SAD) escalation study with four consecutive cohorts, single ascending doses of TTYP01 (60, 120, 180 and 240 mg) will be orally administrated.
Drug: TTYP01 single ascending doses
Placebo control for Part A of the study
Drug: Placebo
Randomized, Open-label, Four-period and Crossover design. A single dose of edaravone in each treatment period. Period 1: 60 mg oral edaravone tablet (TTYP01); Period 2: 30 mg IV edaravone (Radicut® ampoule), Period 3: 120 mg oral edaravone tablet (TTYP01); Period 4: 60 mg IV edaravone (Radicut® bag). Each dose will be spearated by a minimum of 7 days washout period.
Drug: TTYP01, 60 mg · Drug: TTYP01, 120 mg · Drug: Radicut® (ampoule), 30 mg · Drug: Radicut® (bag) , 60 mg
Randomized, Open-label, Four-period and Crossover design. A single dose of edaravone in each treatment period. Period 1: 30 mg IV edaravone (Radicut® ampoule); Period 2: 60 mg oral edaravone tablet (TTYP01); Period 3: 60 mg IV edaravone (Radicut® bag); Period 4: 120 mg oral edaravone tablet (TTYP01). Each dose will be spearated by a minimum of 7 days washout period.
Drug: TTYP01, 60 mg · Drug: TTYP01, 120 mg · Drug: Radicut® (ampoule), 30 mg · Drug: Radicut® (bag) , 60 mg
Randomized, open-Label, Two-period and Crossover design. A fix oral dose of TTYP01 tablet in each treatment period. Period 1: under fasted condition; Period 2: under fed condition. Each dose will be spearated by a minimum of 7 days washout period.
Drug: TTYP01, up to 120 mg
Randomized, open-Label, Two-period and Crossover design. A fix oral dose of TTYP01 tablet in each treatment period. Period 1: under fed condition; Period 2: under fasted condition. Each dose will be spearated by a minimum of 7 days washout period.
Drug: TTYP01, up to 120 mg
TTYP01 (30 mg edaravone tablet) will be orally administrated at single ascending doses of 60 mg, 120 mg, 180 mg and 240 mg (n=6 per dose)
Also known as: edaravone tablet
Placebo control for Part A of the study
TTYP01 oral tablets (30 mg edaravone per tablet)
Also known as: Edaravone tablet
TTYP01 oral tablets (30 mg edaravone per tablet)
Also known as: Edaravone tablet
An intravenous dose of edaravone injection, containing 30 mg edaravone in a 20 mL ampoule, will be administered at a dose of 30 mg over 30 minutes
Also known as: Edaravone injection
An intravenous dose of edaravone injection, containing 30 mg edaravone in a 100 mL injection bag, will be administered at a dose of 60 mg over 60 minutes
Also known as: Edaravone injection
TTYP01 oral tablets (30 mg edaravone per tablet). The fixed oral dose level of TTYP01 will depend on the results obtained in Part B of the study (no more than 120 mg)
Also known as: Edaravone tablet
Adverse events
Frequencies (number and percentage) of subjects with one or more AEs
Time frame: until the last follow-up visit, up to 4 weeks
change in hemoglobin (g/L)
measured by hematology test
Time frame: up to 6 days post each dose
change in hematocrit (ratio)
measured by hematology test
Time frame: up to 6 days post each dose
change in red blood cell count (cells x 10^12/L)
measured by hematology test
Time frame: up to 6 days post each dose
change in white blood cell (WBC) count (cells x 10^9/L)
measured by hematology test
Time frame: up to 6 days post each dose
change in platelet count (cells x 10^9/L)
measured by hematology test
Time frame: up to 6 days post each dose
change in total neutrophils count (cells x 10^9/L)
measured by hematology test
Time frame: up to 6 days post each dose
change in lymphocytes count (cells x 10^9/L)
measured by hematology test
Time frame: up to 6 days post each dose
change in monocytes count (cells x 10^9/L)
measured by hematology test
Time frame: up to 6 days post each dose
change in eosinophils count (cells x 10^9/L)
measured by hematology test
Time frame: up to 6 days post each dose
change in basophils count (cells x 10^9/L)
measured by hematology test
Time frame: up to 6 days post each dose
change in serum sodium (mmol/L)
measured by serum chemistry
Time frame: up to 6 days post each dose
change in serum potassium (mmol/L)
measured by serum chemistry
Time frame: up to 6 days post each dose
change in serum chloride (mmol/L)
measured by serum chemistry
Time frame: up to 6 days post each dose
change in serum calcium (mmol/L)
measured by serum chemistry
Time frame: up to 6 days post each dose
change in serum glucose (mmol/L)
measured by serum chemistry
Time frame: up to 6 days post each dose
change in serum urea (mmol/L)
measured by serum chemistry
Time frame: up to 6 days post each dose
change in serum creatinine (umol/L)
measured by serum chemistry
Time frame: up to 6 days post each dose
change in serum total bilirubin (umol/L)
measured by serum chemistry
Time frame: up to 6 days post each dose
change in aspartate aminotransferase (AST) (U/L)
measured by serum chemistry
Time frame: up to 6 days post each dose
change in alanine aminotransferase (ALT) (U/L)
measured by serum chemistry
Time frame: up to 6 days post each dose
change in alkaline phosphatase (ALP) (U/L)
measured by serum chemistry
Time frame: up to 6 days post each dose
change in serum creatine kinase (CK) (U/L)
measured by serum chemistry
Time frame: up to 6 days post each dose
change in serum albumin (g/L)
measured by serum chemistry
Time frame: up to 6 days post each dose
change in serum phosphate (mmol/L)
measured by serum chemistry
Time frame: up to 6 days post each dose
change in serum lipase (U/L)
measured by serum chemistry
Time frame: up to 6 days post each dose
change in serum total protein (g/L)
measured by serum chemistry
Time frame: up to 6 days post each dose
change in urine pH
measured by urinalysis
Time frame: up to 6 days post each dose
change in urine specific gravity
measured by urinalysis
Time frame: up to 6 days post each dose
change in urine glucose
measured by urinalysis
Time frame: up to 6 days post each dose
change in urine protein
measured by urinalysis
Time frame: up to 6 days post each dose
change in urine ketones
measured by urinalysis
Time frame: up to 6 days post each dose
change in urine blood
measured by urinalysis
Time frame: up to 6 days post each dose
change in urine casts
measured by microscopic analysis, if any abnormalities in urinalysis are detected
Time frame: up to 6 days post each dose
change in urine crystals
measured by microscopic analysis, if any abnormalities in urinalysis are detected
Time frame: up to 6 days post each dose
change in urine epithelial cells
measured by microscopic analysis, if any abnormalities in urinalysis are detected
Time frame: up to 6 days post each dose
change in urine bacteria (cfu/L)
measured by microscopic analysis, if any abnormalities in urinalysis are detected
Time frame: up to 6 days post each dose
change in urine red blood cells (Cells x 10^9/L)
measured by microscopic analysis, if any abnormalities in urinalysis are detected
Time frame: up to 6 days post each dose
change in urine white blood cells (Cells x 10^9/L)
measured by microscopic analysis, if any abnormalities in urinalysis are detected
Time frame: up to 6 days post each dose
change in systolic blood pressure (mmHg)
Time frame: up to 6 days post each dose
change in diastolic blood pressure (mmHg)
Time frame: up to 6 days post each dose
change in pulse rate (bpm)
Time frame: up to 6 days post each dose
change in body temperature (celsius)
Time frame: up to 6 days post each dose
Change in QT intervals (msec)
Measured using a 12 Lead Electrocardiogram
Time frame: up to 6 days post each dose
Change in RR intervals (msec)
Measured using a 12 Lead Electrocardiogram
Time frame: up to 6 days post each dose
Change in PR intervals (msec)
Measured using a 12 Lead Electrocardiogram
Time frame: up to 6 days post each dose
Change in QRS duration (msec)
Measured using a 12 Lead Electrocardiogram
Time frame: up to 6 days post each dose
Change in corrected QTcF (msec)
Calculated using measurements by a 12 Lead Electrocardiogram
Time frame: up to 6 days post each dose
clinically significant abnormality in brief physical examinations
clinically significant abnormality in skin, lungs, cardiovascular system, and abdomen (spleen and liver)
Time frame: up to 6 days post each dose
Maximum observed plasma concentration (Cmax)
Time frame: up to 24 hours post each dose
Time of maximum plasma concentration (Tmax)
Time frame: up to 24 hours post each dose
Area under the plasma concentration-time curve from time-zero extrapolated to infinite time (AUC0-inf)
Time frame: up to 24 hours post each dose
Area under the plasma concentration-time curve from time-zero to the time of the last measurable concentration (AUC0-last)
Time frame: up to 24 hours post each dose
The ratio of area under the plasma concentration-time curve from time-zero to the time of the last measurable concentration (AUC0-last) extrapolated to AUC0-inf over AUC0-inf (% AUCex)
Time frame: up to 24 hours post each dose
Apparent volume of distribution (Vd/F)
Time frame: up to 24 hours post each dose
Terminal half-life(T1/2)
Time frame: up to 24 hours post each dose
Apparent oral clearance (CL/F)
Time frame: up to 24 hours post each dose
Mean retention time (MRT)
Time frame: up to 24 hours post each dose
Lambda z - the reciprocal of elimination rate constant (λz)
Time frame: up to 24 hours post each dose
Fabs-bioavailability value (Fabs)
Time frame: up to 24 hours post each dose
Ran from Apr 2020 to primary completion in Dec 2020, 7 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Shanghai Auzone Biological Technology Co., Ltd.